论文部分内容阅读
目的:探讨FTO基因在原发性乳腺癌组织中的表达及新辅助化疗对其表达的影响。方法:应用RT-PCR方法检测28例乳腺增生病组织和24例乳腺癌组织及10例乳腺癌新辅助化疗前后组织中FTO mRNA的表达水平,并分析FTO基因表达水平与乳腺癌患者临床病理参数的关系。结果:FTO基因在乳腺增生组织及乳腺癌组织均有表达,而在乳腺癌表达高于乳腺增生组织(P<0.05);新辅助化疗后乳腺癌组织FTO mRNA的表达水平低于化疗前(P<0.05);乳腺癌组织FTO mRNA表达水平与淋巴结转移有关,FTO mRNA的表达量在淋巴结转移组高于未转移组(P<0.05),而与ER,PR受体,CerbB-2基因状态及肥胖无关(均P>0.05)。结论:FTO基因在乳腺癌组织中表达增加,且可能与乳腺癌发生发展有关;新辅助化疗可以下调乳腺癌组织FTO基因的表达。
Objective: To investigate the expression of FTO gene in primary breast cancer and the effect of neoadjuvant chemotherapy on its expression. METHODS: RT-PCR was used to detect the expression of FTO mRNA in tissues of 28 cases of breast hyperplasia, 24 cases of breast cancer, and 10 cases of breast cancer before and after neoadjuvant chemotherapy. The expression of FTO gene and the clinicopathological parameters of breast cancer patients were analyzed. Relationship. RESULTS: FTO gene was expressed in breast hyperplasia and breast cancer tissues, but it was higher in breast cancer than in breast hyperplasia (P<0.05). The expression of FTO mRNA in breast cancer tissues after neoadjuvant chemotherapy was lower than that before chemotherapy (P<0.05). <0.05); The expression of FTO mRNA in breast cancer tissues was related to lymph node metastasis. The expression of FTO mRNA was higher in lymph node metastasis group than in non-metastasis group (P<0.05), while it was associated with ER, PR receptor, and CerbB-2 gene status. Obesity was unrelated (all P>0.05). Conclusion: The expression of FTO gene is increased in breast cancer tissues and may be related to the development of breast cancer. Neoadjuvant chemotherapy can down-regulate the expression of FTO gene in breast cancer tissues.